1. Home
  2. Media
  3. News
  4. Bioiberica Heparin Science, to be present at DCAT Week 2017

Bioiberica Heparin Science, to be present at DCAT Week 2017

20 Mar 2017
Heparin
  • Bioiberica’s heparin business unit has the aim of establishing strategic partnerships and finding new business opportunities 
  • This is the largest professional and business meeting of the pharma industry, which will include high level meetings, networking sessions and educational programs 
  • It is expected that this year’s edition will register the largest attendance in their history 

As in previous years, Bioibérica Heparin Science, Bioiberica’s business unit specializing in the research, development, production and marketing of heparin, will attend DCAT Week, which will be held in New York this week. The aim of DCAT Week is establishing strategic partnerships and finding new business opportunities. 

DCAT Week is the ideal venue for these types of contacts, for it is not a standard fair, but a week of pre-scheduled meetings between customers, providers and potential commercial partners. 

Hosted by the Drug Chemical and Associated Technologies (DCAT) association, this is the largest professional and business meeting in the pharma industry, and includes high level meetings, networking sessions and educational programs. Its unique model brings industry CEOs, presidents, global marketing directors and supply chain managers from the entire pharmaceutical world. 

Heparin is the product in which Bioiberica has been specializing since their beginning in 1975, becoming the world leader in the production of this anticoagulant and anti thrombin drug. More precisely, one out of five heparin doses administered worldwide has been developed and manufactured in Spain by Bioiberica.